- LIXTE’s lead compound, LB-100, is the world’s first and only clinical-stage inhibitor of protein phosphatase 2A (“PP2A”).
- LB-100 helps in the fight against cancer in a few ways, as it makes cancer cells more sensitive to immunotherapy and chemotherapy, while also disrupting cancer’s internal repair system.
- The compound has demonstrated a favorable safety profile in Phase 1 clinical trials and has been supported by over 25 published preclinical and translational studies so far.
LIXTE Biotechnology Holdings (NASDAQ: LIXT), a clinical-stage pharmaceutical company, is in the unique position of holding the world’s only clinical-stage protein phosphatase 2A (“PP2A”) inhibitor, called LB-100.
Questions around this news
How is LB-100 intended to affect cancer treatment?
The release describes LB-100 as a compound designed to inhibit PP2A. It says the compound may make cancer cells more responsive to immunotherapy and chemotherapy and interfere with cancer cells’ repair processes. These are the proposed ways it could affect treatment; the release does not provide clinical results showing that it improves patient outcomes.
What does the release say about LB-100’s clinical testing and safety?
The release says LB-100 has been evaluated in Phase 1 clinical trials and reports a favorable safety profile in those trials. It does not give trial details, such as the number of participants, specific side effects, or study results. Phase 1 testing generally focuses on initial safety and tolerability in people.
What does “clinical-stage” mean for a drug candidate?
A clinical-stage drug candidate has entered testing in people through clinical trials. That status does not by itself establish that the candidate is effective, has been approved, or will reach the market. Clinical development typically involves studies designed to examine safety and, as development proceeds, how well a treatment works.
The LB-100 compound is a proprietary small-molecule PP2A inhibitor that is designed to target protein phosphatase 2A (“PP2A”), introducing a potential new treatment paradigm aimed at enhancing existing…
NOTE TO INVESTORS: IBN is a multifaceted financial news, content creation and publishing company utilized by both public and private companies to optimize investor awareness and recognition. For more information, please visit https://www.InvestorBrandNetwork.com
Please see full terms of use and disclaimers on the InvestorBrandNetwork website applicable to all content provided by IBN, wherever published or re-published: http://IBN.fm/Disclaimer
The latest news and updates relating to LIXT are available in the company’s newsroom at https://ibn.fm/LIXT
Corporate Communications
IBN
Austin, Texas
www.InvestorBrandNetwork.com
512.354.7000 Office
[email protected]
At a glance
- Company
- LIXTE Biotechnology Holdings
- Ticker
- NASDAQ: LIXT
- Announcement
- Product
Key figures
- Published preclinical and translational studies
- over 25
- Clinical trial phase cited
- Phase 1
Products and programs
Earlier from LIXTE Biotechnology Holdings
- LIXTE Biotechnology (NASDAQ: LIXT) Strengthens Oncology Pipeline Through Expanded LB-100 Clinical Trials
- Lixte Biotech (NASDAQ: LIXT) Advances Precision Oncology with LB-100, Strengthens Position Through Liora Technologies Partnership
- Landmark Proton Therapy Data Changes the Conversation; LIXTE Biotechnology (NASDAQ: LIXT) Saw It Coming
- LIXTE Biotechnology (NASDAQ: LIXT) Advances PP2A Inhibition Strategy in Evolving Oncology Landscape
- LIXTE Biotechnology Holdings (NASDAQ: LIXT) Adds Innovative LiGHT Therapy to Pipeline
